PPA
PBYI icon

Parametric Portfolio Associates’s Puma Biotechnology PBYI Stock Holding History

Parametric Portfolio Associates’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.13M Sell
392,321
-5,162
-1% -$13.4K ﹤0.01% 2725
2021
Q4 		$1.21M Buy
397,483
+140,057
+54% +$608K ﹤0.01% 2705
2021
Q3 		$1.8M Buy
257,426
+208,845
+430% +$1.56M ﹤0.01% 2496
2021
Q2 		$446K Buy
48,581
+24,493
+102% +$248K ﹤0.01% 3133
2021
Q1 		$234K Buy
24,088
+8,432
+54% +$94.2K ﹤0.01% 3814
2020
Q4 		$161K Sell
15,656
-40,126
-72% -$406K ﹤0.01% 3825
2020
Q3 		$563K Buy
55,782
+9,961
+22% +$101K ﹤0.01% 3212
2020
Q2 		$478K Sell
45,821
-25,308
-36% -$262K ﹤0.01% 3296
2020
Q1 		$600K Sell
71,129
-119,016
-63% -$1.16M ﹤0.01% 3070
2019
Q4 		$1.66M Buy
190,145
+101,334
+114% +$839K ﹤0.01% 2804
2019
Q3 		$956K Buy
88,811
+39,916
+82% +$431K ﹤0.01% 3049
2019
Q2 		$621K Sell
48,895
-60,174
-55% -$1.39M ﹤0.01% 3276
2019
Q1 		$4.23M Buy
109,069
+91,163
+509% +$2.78M ﹤0.01% 2118
2018
Q4 		$364K Sell
17,906
-30,223
-63% -$907K ﹤0.01% 3449
2018
Q3 		$2.21M Buy
48,129
+6,273
+15% +$302K ﹤0.01% 2648
2018
Q2 		$2.48M Buy
41,856
+9,475
+29% +$549K ﹤0.01% 2539
2018
Q1 		$2.2M Sell
32,381
-1,893
-6% -$142K ﹤0.01% 2552
2017
Q4 		$3.39M Buy
34,274
+19,246
+128% +$2.15M ﹤0.01% 2217
2017
Q3 		$1.8M Buy
15,028
+7,184
+92% +$668K ﹤0.01% 2663
2017
Q2 		$686K Buy
7,844
+936
+14% +$52.4K ﹤0.01% 3189
2017
Q1 		$257K Buy
+6,908
New +$252K ﹤0.01% 3497
2016
Q4 		– Sell
-14,626
Closed -$981K – 3798
2016
Q3 		$981K Buy
+14,626
New +$740K ﹤0.01% 2820
2016
Q1 		– Sell
-5,234
Closed -$410K – 4013
2015
Q4 		$410K Sell
5,234
-3,592
-41% -$282K ﹤0.01% 3383
2015
Q3 		$665K Buy
8,826
+4,424
+100% +$418K ﹤0.01% 2574
2015
Q2 		$514K Sell
4,402
-1,249
-22% -$226K ﹤0.01% 3265
2015
Q1 		$1.33M Buy
5,651
+1,833
+48% +$392K ﹤0.01% 2558
2014
Q4 		$723K Buy
+3,818
New +$847K ﹤0.01% 3029
2014
Q2 		– Sell
-2,118
Closed -$221K – 3778
2014
Q1 		$221K Buy
+2,118
New +$249K ﹤0.01% 3581

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Parametric Portfolio Associates's PBYI Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Puma Biotechnology (PBYI) stake by 1.3% in Q1 2022, selling an estimated $13.4K and leaving 392,321 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2725.

Parametric Portfolio Associates first reported a position in PBYI in Q1 2014 and has held it in 28 quarters since. The position peaked at $4.23M in Q1 2019. 104 funds tracked by Wall St. Rank hold PBYI as of Q1 2022.

  • Parametric Portfolio Associates held 392,321 shares of Puma Biotechnology worth $1.13M as of Q1 2022.
  • Parametric Portfolio Associates sold 5,162 Puma Biotechnology shares in Q1 2022, an estimated $13.4K.
  • Puma Biotechnology made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2725 holding.
  • Parametric Portfolio Associates first reported a position in Puma Biotechnology in Q1 2014 and has held it in 28 quarters since.
  • Parametric Portfolio Associates's Puma Biotechnology position peaked at $4.23M in Q1 2019.
  • 104 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.